双歧杆菌三联活菌胶囊对溃疡性结肠炎患者血清白介素-6、8和10水平的影响及疗效观察

目的探讨双歧杆菌三联活菌胶囊对溃疡性结肠炎（UC）患者血清白介素（IL）-6、8和10水平的影响及疗效观察。方法选取88例UC患者,随机分为观察组和对照组。两组患者均酌情予以柳氮磺胺吡啶、5-氨基水杨酸和糖皮质激素等常规治疗。观察组患者在此基础上加用口服双歧杆菌三联活菌胶囊420mg/次,3次/d,连用8周。对照组患者除不使用双歧杆菌三联活菌胶囊外余治疗同观察组。观察两组患者治疗前后血清IL-6、8和10水平变化,并比较其临床疗效及不良反应。结果治疗8周后,两组患者血清IL-6、8水平明显下降,IL-10水平明显上升（P〈0.05或P〈0.01）,且观察组下降值或上升值大于对照组（P〈0.05）;观察组患者总有效率明显高于对照组（χ2=4.42,P〈0.05）;治疗中对照组出现不良反应3例,观察组出现5例,症状均较轻,两组患者不良反应发生率比较差异无统计学意义（χ2=0.14,P〉0.05）。结论双歧杆菌三联活菌胶囊治疗UC的疗效确切,安全性较好,作用与其能降低血清IL-6、8水平,提高血清IL-10水平,减轻肠黏膜局部炎症反应密切相关。

Influence and curative effect of Bifid Triple Viable Capsules on serum interleukin-6,8 and 10 levels of patients with ulcerative colitis

Objective To discuss the influence and curative effect of Bifid Triple Viable Capsules on serum Interleukin-6,8 and 10（ IL-6,IL-8 and IL-10） levels of patients with ulcerative colitis（ UC）. Methods 88 patients with UC were selected and divided into observation group and control group at random. Both groups were given routine medication including sulfasalazine（ SSZ）,5-aminosalicylic acid（ 5-ASA） and glucocorticoid etc as appropriate. The observation group was additionally given 420 mg Bifid Triple Viable Capsules t. i. d. orally for 8 weeks.The changes of serum IL-6,8 and 10 levels of patients before and after treatment were observed,and the clinical efficacy and adverse reactions were compared between the two groups. Results The serum IL-6 and IL-8 levels obviously declined while IL-10 obviously increased in both groups after treatment（ P 〈 0. 05 or P 〈 0. 01）,with the declining or increasing value in observation group much higher than those in control group（ P 〈 0. 05）. The total clinical efficiency in observation group was much higher than that in control group（ χ2= 4. 42,P 〈 0. 05）. 3 and 5cases of adverse reactions with mild symptoms appeared in control group and observation group respectively during the treatment,and the difference in the occurrence rate of adverse reaction was not significant（ χ2= 0. 14,P 〉0. 05）. Conclusion Bifid Triple Viable Capsules has reliable curative effect on UC,with favorable safety profile.The mechanism may be closely related to its ability to reduce the serum IL-6 and IL-8 levels,raising serum IL-10 level and reducing the intestinal mucosal inflammation reaction.